Pooling five randomized, double-blind, placebo-controlled trials (N = 1,730) — BrigHTN, HALO, BaxHTN, FigHTN, and Bax24 — this meta-analysis finds that baxdrostat, a highly selective CYP11B2 inhibitor (100:1 selectivity over CYP11B1), reduces seated systolic blood pressure by a placebo-corrected 6.90 mmHg (95% CI: −10.25 to −3.55). The 2 mg dose drove the strongest effect (−8.16 mmHg), while 0.5 mg failed to reach significance. Importantly, baxdrostat nearly tripled the odds of achieving the guideline target of SBP < 130 mmHg (OR 2.70). The principal safety signal was hyperkalemia — 8.9% versus 1.2% with placebo — with severe elevations (K⁺ > 6.0 mmol/L) in 3.8% of treated patients, though no attributable deaths occurred.
Resistant hypertension — blood pressure uncontrolled despite three or more agents — remains one of the highest-risk cardiovascular phenotypes, strongly linked to stroke, heart failure, and renal disease. Existing options like spironolactone and eplerenone address aldosterone excess but carry off-target hormonal effects; baxdrostat's upstream synthase inhibition offers a mechanistically cleaner approach. A nearly 7 mmHg systolic reduction is clinically meaningful: population-level data suggest each 5 mmHg reduction corresponds to roughly 10% fewer major cardiovascular events. However, high heterogeneity (I² = 74–89%) across trials tempers confidence, and the hyperkalemia signal demands careful monitoring, particularly in patients with chronic kidney disease. This is an incremental but genuinely promising advance for a population with limited pharmaceutical options, and regulatory scrutiny of longer-term outcomes data will be the critical next step.